PDCD1 and melanoma: As expected, IPS score, IPS-PD-1 blocker score, IPS-CTLA4 blocker score and IPS-PD-1-CTLA4 blocker score were higher in melanoma patients with low risk scores (all P < 0.001) (Fig. 8A), elucidating that melanoma patients in the low-risk group might benefit more from immunotherapy.